logo
Search
  • POA Pharma Scandinavia AB expands the partnership with Orpharma, Melbourne, AUSTRALIA.

    Antisecretory Factor (AF) is a protein secreted in plasma and tissue fluids in mammals. This 41-kDA protein provides protection against diarrheal diseases and intestinal inflammation. The AF protein is induced by cholera toxin and was first isolated and characterized by Swedish researchers Lange and Lönnroth in the 80´s. Immunocytochemistry has shown that AF is present in most tissues. The endogenous plasma level of AF is increased by enterotoxins and surprisingly also by certain food constituents. Based on these findings, AF inducing medical food have been developed. SPC Flakes® is an AF-inducing medical food and alovum®  (B221) is an AF-rich egg yolk powder.

    Clinical trials in Crohn´disease and short bowel syndrome has shown that AF exerts both antisecretory effects and anti-inflammatory effects.

    Because of the effects on hypersecretion in the GI tract it was hypothesized that AF treatment could be valuable in other instances were fluid balance is thought to play a role, such as Ménière´s disease.

    This has been proven in four published studies out of them two are  double blinded and one a cross-over trial.

     

    Orpharma

    Orpharma is an Australian pharmaceutical company focused on the supply of orphan, paediatric and emerging therapeutics. The company was founded to serve unmet medical needs and to provide niche solutions. Orpharma is collaborating with global leaders in biotechnology and pharmaceuticals to deliver therapies to patients in need. Giving a ray of hope.

    Orpharma’s current product portfolio includes innovative medicines targeting rare metabolic diseases, cancer and anti-infective (http://www.orpharma.com).

     

    POA Pharma – The Boutique Healthcare Company

     

    Brief History

    POA Pharma was on the market March 2011. Today the company have offices in four Nordic countries and in US. POA Pharma works within nine different competence areas having export agreements with 30 countries and agreements with pharmaceutical producers in 11 countries.

     

    An Export Company.

    Since 2013, POA Pharma have signed distribution agreements for it´s metabolic assortment in 27 countries; Australia, Argentina, Bolivia, Botswana, Brazil, Canada, Chile, Colombia, Czech Republic, Holland, Honduras, 
Ireland, Island, Italy, Malaysia, Mexico
, Mozambique, Namibia, New Zeeland, Singapore, Slovakia,
 South Africa, Turkey
, UK, USA,
 Uruguay, Zimbabwe, 

    A Boutique Company

    POA Pharma is a market oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and pharmacies in the 26 million population Nordic countries.  

    Boutique is French for “shop”, via Latin from Greek apothēkē, “sto, rehouse”. In contemporary business language boutique is a specialized firm with a unique concept.

     “ A Boutique is where you expect to be positive surprised when finding what the average shop cannot offer. “

     

     

    For more information please contact Tina Madsen Sandström, or Hala Raghib,

     

     

    Leave a reply →